NAYA Biosciences Stock Price, News & Analysis
Company Description
NAYA (Nasdaq: NAYA) historically referred to NAYA Biosciences, Inc., a life science portfolio company described in multiple news releases as being dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, women’s health, and fertility. The company’s model was characterized as a hub-and-spoke structure that used the shared resources of a parent organization to support lean, strategic franchises, combining commercial fertility operations with clinical‑stage therapeutic programs.
According to company news disclosures, NAYA Biosciences’ portfolio of assets included several bifunctional or bispecific antibody candidates and a fertility technology asset. The oncology and autoimmune pipeline featured NY-303, a GPC3 x NKp46 or GPC3 and NKp46 targeting antibody for hepatocellular carcinoma (HCC) with a mode of action aimed at non‑responders to the prevailing immunotherapy standard of care; NY-338, a CD38 x NKp46 or CD38 and NKp46 targeting antibody for multiple myeloma and autoimmune diseases; NY-500, a PD‑1 x VEGF tetravalent bifunctional antibody candidate for HCC and other solid tumors; and NY-600, a PSMA x NKp46 bifunctional antibody for metastatic castration‑resistant prostate cancer (mCRPC). Company communications also describe use of a proprietary FLEX antibody format and AI‑enabled optimization in the design of certain candidates.
In the fertility and women’s health area, NAYA‑related disclosures describe the INVOcell medical device and associated intravaginal culture (IVC) procedure. INVOcell is described as an FDA‑cleared, in vivo intravaginal culture system that allows fertilization and early embryo development to occur within the woman’s body rather than in a laboratory incubator. Company materials state that this approach is intended to provide a more natural, intimate, and economical assisted reproductive technology (ART) option, and that it has demonstrated comparable success rates to traditional in vitro fertilization (IVF) while offering a different patient experience compared with intrauterine insemination (IUI) and conventional IVF.
News releases further explain that the commercial fertility strategy involved operating fertility‑focused clinics under the INVO Centers brand and a conventional IVF clinic, as well as selling and distributing INVOcell to independently owned and operated fertility clinics. These activities were described as revenue‑generating operations within the broader portfolio structure.
A significant corporate development for investors researching the NAYA ticker is the merger and subsequent renaming of the public company. A Globe Newswire announcement dated October 21, 2024 states that INVO Biosciences changed its corporate name to NAYA Biosciences Inc. and began trading under the symbol “NAYA” on October 22, 2024, following completion of a merger with NAYA Biosciences. Later, an April 14, 2025 news release reports that the public company was renamed INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., and that the Nasdaq ticker symbol would be changed from “NAYA” to “IVF” as soon as practicable. A subsequent April 24, 2025 announcement confirms that the company would begin trading under the new symbol “IVF” on April 28, 2025, with the CUSIP for the common stock remaining unchanged.
These communications explain that the corporate structure was revised to separate fertility and oncology operations into distinct entities. The public company, renamed INVO Fertility, Inc., is described as a healthcare services fertility company focused on building, acquiring and operating fertility clinics and distributing the FDA‑cleared INVOcell device. A separate private company, NAYA Therapeutics, Inc., is described as a clinical‑stage biopharmaceutical company focusing on next‑generation bifunctional antibodies in oncology, with assets such as NY‑303, NY‑500, and NY‑338. The public company indicated an intention to retain a minority stake in NAYA Therapeutics while concentrating its own efforts on fertility services.
For users examining the historical NAYA symbol, this means that NAYA represents a sequence of corporate identities: initially associated with NAYA Biosciences as a life science portfolio company, then with the combined entity following its merger with INVO Biosciences, and ultimately transitioning to INVO Fertility, Inc. under the Nasdaq symbol “IVF.” The historical description of NAYA therefore encompasses both a diversified life science portfolio model and, later, a more focused fertility services company with clinic operations and a proprietary reproductive technology device.
Business focus and operating model (historical)
Company disclosures describe the historical NAYA Biosciences model as a hub‑and‑spoke structure. Under this approach, the parent entity provided shared resources while individual franchises pursued specific therapeutic or fertility opportunities. The stated goal was to combine scalable, profitable commercial revenues from fertility operations with the potential upside of clinical‑stage therapeutics in oncology and autoimmune diseases. This combination is presented in company materials as a way to balance near‑term revenue generation with longer‑term value from drug development programs.
Within oncology, the pipeline assets are repeatedly characterized as bifunctional or bispecific antibodies designed to engage targets such as GPC3, NKp46, CD38, PD‑1, VEGF, and PSMA. Company communications highlight mechanisms such as engaging natural killer (NK) cells, targeting oncofetal proteins like GPC3 on liver cancer cells, and simultaneously modulating immune checkpoints and angiogenesis pathways. These descriptions emphasize the intent to address patients who do not respond adequately to existing immunotherapies, particularly in hepatocellular carcinoma.
Within fertility, the company’s disclosures focus on assisted reproductive technology (ART) and fertility clinic operations. INVO Centers and a conventional IVF clinic are presented as treatment sites, while INVOcell and the IVC procedure are described as a distinct technology and process that use the woman’s body as a natural incubator for fertilization and early embryo development. Company statements link this approach to goals of improving access, affordability, and patient experience in fertility care.
Corporate evolution and ticker transition
For investors, one of the most important aspects of the NAYA symbol is its transformation over time. The October 21, 2024 announcement notes that INVO Biosciences changed its name to NAYA Biosciences Inc. and began trading as “NAYA” on October 22, 2024, following a merger that combined fertility operations with oncology and autoimmune disease programs. Later, the April 14, 2025 release explains that the public company was renamed INVO Fertility, Inc., formerly known as NAYA Biosciences, Inc., and that the Nasdaq ticker symbol would change to “IVF.” The April 24, 2025 release then confirms that trading under “IVF” would begin on April 28, 2025.
As a result, the NAYA ticker now serves primarily as a historical reference point. Current trading and ongoing public‑company disclosures are associated with INVO Fertility, Inc. under the symbol IVF, while NAYA Therapeutics, Inc. operates as a private biopharmaceutical company. Users researching NAYA should therefore consider both the legacy life science portfolio description and the subsequent fertility‑focused profile under the INVO Fertility name.